Literature DB >> 9278317

CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response.

A I Jaiswal1, M Croft.   

Abstract

Recent data suggest that CD40 ligand (CD40L)-CD40 interactions are essential for up-regulation of costimulatory activity on APC and that efficient induction of CD40L may be pivotal to the success of a CD4 T cell response. CD40L is regulated primarily by TCR signaling, but high level expression on a naive T cell appears to require additional interactions between T cell coreceptors and APC accessory molecules. The data reported here show that resting B cells presenting peptide Ag, in contrast to both dendritic cells and preactivated B cells, induce very little CD40L on naive CD4 cells, which in turn is insufficient to promote APC costimulatory activity. We also show, however, that previously activated effector T cells have enhanced responsiveness to Ag when accessory molecule help is limiting and consequently can express high levels of CD40L after interaction with resting B cells. High level CD40L expression correlated with B cell activation and up-regulation of costimulatory activity; however, blocking studies showed that CD40L was only partially responsible for these phenomena. These studies reinforce the notion that resting B cells may be tolerogenic for naive CD4 cells in part because of inefficient CD40L induction. The data also suggest that a successful primary T cell response will only occur if either the initial interaction is with a dendritic cell followed by subsequent interactions of the effector T cells with resting APC or if nonspecific inflammatory stimuli up-regulate accessory molecule expression on resting APC before an encounter with the naive T cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278317

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

Authors:  Loren D Erickson; Brigit G Durell; Laura A Vogel; Brian P O'Connor; Marilia Cascalho; Teruhito Yasui; Hitoshi Kikutani; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Protective role for interleukin-5 during chronic Toxoplasma gondii infection.

Authors:  Y Zhang; E Y Denkers
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets.

Authors:  Takuya Koike; Koshi Harada; Shu Horiuchi; Daisuke Kitamura
Journal:  Elife       Date:  2019-06-21       Impact factor: 8.140

4.  Abnormal CD40 ligand (CD154) expression in human immunodeficiency virus-infected children.

Authors:  M R O'Gorman; B DuChateau; M Paniagua; J Hunt; N Bensen; R Yogev
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

Review 5.  An immunology primer for computational modelers.

Authors:  William F Hawse; Penelope A Morel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-09-20       Impact factor: 2.745

6.  Functional cooperation between T helper cell determinants.

Authors:  M Gerloni; S Xiong; S Mukerjee; S P Schoenberger; M Croft; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Human CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expression.

Authors:  Sagarika Chakrabarty; James T Snyder; Jijia Shen; Hooman Azmi; Paul Q Hu; Qian Chen; Jack A Ragheb
Journal:  Blood       Date:  2010-07-15       Impact factor: 22.113

8.  CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.

Authors:  Tahamtan Ahmadi; Amanda Flies; Yvonne Efebera; David H Sherr
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

9.  Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.

Authors:  S Guo; J Xu; W Denning; Z Hel
Journal:  Gene Ther       Date:  2009-07-30       Impact factor: 5.250

10.  Exploiting human memory B cell heterogeneity for improved vaccine efficacy.

Authors:  Noel T Pauli; Carole J Henry Dunand; Patrick C Wilson
Journal:  Front Immunol       Date:  2011-12-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.